Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Clovis Oncology Inc (NASDAQ:CLVS)

60.94
Delayed Data
As of Nov 24
 0.00 / 0.00%
Today’s Change
34.04
Today|||52-Week Range
99.45
+37.19%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$3.0B

Company Description

Clovis Oncology, Inc. engages in the acquisition, development, and commercialization of anti-cancer agents. Its marketed product, Rubraca, seeks to treat patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies. It also has product candidates, namely Rociletinib and Lucitanib. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

Contact Information

Clovis Oncology, Inc.
5500 Flatiron Parkway
Boulder Colorado 80301
P:(303) 625-5000
Investor Relations:
(303) 625-5023

Employees

Shareholders

Other institutional57.68%
Mutual fund holders46.88%
Individual stakeholders10.94%

Top Executives

Patrick J. MahaffyPresident, Chief Executive Officer & Director
Daniel W. MuehlPrincipal Financial Officer & SVP-Finance
Gillian C. Ivers-ReadChief Regulatory Officer & Executive VP
Lindsey RolfeChief Medical Officer & Executive VP-Clinical
Paul E. GrossSecretary, Chief Compliance Officer & Senior VP